NCT07201675View on ClinicalTrials.gov

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

59

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions

Muscle Invasive Bladder Cancer (MIBC)

Interventions

DRUG

RC48-ADC combined with toripalimab for bladder-sparing therapy

RC48-ADC combined with toripalimab for bladder-sparing therapy

All Listed Sponsors

lead

Qilu Hospital of Shandong University

OTHER